AUPH vs BBIO Stock Comparison

AUPH currently leads BBIO in this stock comparison, with AIQ scores of 75 vs 64. The clearest difference is value.

Market data as of Nov 15, 2026 market close· AIQ score gap 11 points
AUPH
Healthcare
vs
BBIO
Healthcare
AUPH
Aurinia Pharmaceuticals Inc.
Leads
Price
$15.73
Day move
-2.96%
AIQ Score
75/100
Best edge
Value
Sector
Healthcare
BBIO
BridgeBio Pharma, Inc.
Price
$78.30
Day move
+0.17%
AIQ Score
64/100
Best edge
Balanced
Sector
Healthcare

What is the main difference between AUPH and BBIO?

AUPH leads the current stock comparison as Aurinia Pharmaceuticals Inc., with the clearest separation coming from value and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

Aurinia Pharmaceuticals Inc. vs BridgeBio Pharma, Inc.

Data as of Nov 15, 2026· market close· Healthcare· Coverage 64/66 fields· High confidence
AIQ VerdictFragileAIQ Comparison Conviction 5/10

AUPH leads

AUPH leads by 11 AIQ points, primarily on Value and Quality, but the lead has narrowed from 23 points over 30 sessions. Wall Street currently favors BBIO on target upside.

Fragile: 3 of 6 evidence groups support AUPH, its lead is narrowing, and its current signal state is conflicted.

Evidence agreement: 3 of 6Comparison trend: Weakening
AUPH

Aurinia Pharmaceuticals Inc.

Leads
AIQ Score
75/100
AIQ Edge Score
10/10
BBIO

BridgeBio Pharma, Inc.

AIQ Score
64/100
AIQ Edge Score
7/10

The Algovestiq AIQ Score currently favors AUPH over BBIO, 75 versus 64 as of Nov 15, 2026. AUPH's advantage is driven primarily by stronger value and quality. AUPH also shows the weaker technical structure relative to its 50-day moving average, though analyst target upside currently favors BBIO. 3 of 6 covered evidence groups favor AUPH today, and the comparison is rated Fragile on stability: only 3 of 6 covered evidence groups agree. AUPH lead: Weakening — the AIQ differential moved from 23 to 11 points over 30 sessions. AUPH leads on all four AIQ factor dimensions. Value is itself one of those four, so a sweep is not explained by valuation alone — it deserves additional scrutiny for unmodeled catalysts, expectations or event risk.

Compare Aurinia Pharmaceuticals Inc. and BridgeBio Pharma, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Price return from daily closes; distributions are not included.

AUPH
-46.1%
BBIO
+69.8%

Price return comparison

Growth of $10,000, price only

AUPH $5,387 · BBIO $16,985

Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.

Compare AUPH and BBIO against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

AUPH advantage
0
BBIO advantage
  • Value84 vs 55
    AUPH +29
  • Quality77 vs 66
    AUPH +11
  • Risk Resilience68 vs 62
    AUPH +6
  • Momentum73 vs 69
    AUPH +4

3 of 6 evidence groups favor AUPH. AUPH’s edge is concentrated in value and quality.

What changed since the last close

Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.

AUPH0 AIQ

Largest factor move: Value +1, not enough on its own to move the overall score.

New signals

  • Price Lost 200-Day MA — bearish, trend, long horizon
  • BB Lower Band Breach — bullish, volatility, short horizon
BBIO+1 AIQ

Largest factor move: Quality +1

No signal started or stopped since the prior session; its 5 active signals are unchanged.

AUPH's lead narrowed by 1 AIQ point in the latest session.

Deeper signal detail for each name lives on its own signals page — AUPH and BBIO both carry a full feed there.

The central trade-off

AUPH (Aurinia Pharmaceuticals Inc.): the stronger current systematic profile, led by value and quality.

BBIO (BridgeBio Pharma, Inc.): the counter-case, on technicals, analyst expectations.

The AIQ Score and Wall Street therefore point in different directions on this pair.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

AUPH

AUPH on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

BBIO

BBIO on combined revenue and EPS growth.

Value

AUPH

AUPH on the peer-relative Value factor, by 29 points.

Momentum

AUPH

AUPH on the Momentum factor, by 4 points.

Lower downside

AUPH

AUPH on Risk Resilience, by 6 points.

Analyst upside

BBIO

BBIO on implied upside to the consensus price target.

AIQ vs Wall Street

The model and the Street disagree here: AIQ favors AUPH, analyst targets favor BBIO. That disagreement is the most useful thing on this page.

MeasureAUPHBBIONote
Implied upside to target+14.4%+42%BBIO has more room
Target dispersion0%+62.1%Lower is tighter analyst agreement
ConsensusBuyBuyContext, not a primary driver
Analysts covering722Higher coverage generally improves confidence

The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

3 of 6 covered evidence groups favor AUPH. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreAUPH75 vs 64
FundamentalsEvenEPS growth -17.2% vs 46.2%; TTM ROE 4.8% vs 3.4%; gross margin 90.7% vs 93.5%; operating margin 48.6% vs -43.4%
ValuationAUPHValue 84 vs 55
TechnicalsBBIOPrice vs 50-day -4.6% vs 11.9%; vs 200-day 0% vs 7.7%
Risk ResilienceAUPHRisk Resilience 68 vs 62
Analyst expectationsBBIOTarget upside 14.4% vs 42%

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of AUPH and BBIO and are excluded from the count.

AIQ Decision Stability

Fragile

The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.

  • The AIQ gap is moderate at 11 points.
  • Only 3 of 6 covered evidence groups agree. (argues the conclusion is provisional)
  • The leader's advantage has been narrowing. (argues the conclusion is provisional)
  • The leader is throwing conflicting signals. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on AUPH.

How the comparison changed

120 daily snapshots · May 27 – Nov 13

AUPH lead: Weakening — the AIQ differential moved from 23 to 11 points over 30 sessions.

May 27AUPH leads above the line · BBIO leads belowNov 13
Today
AUPH +11
75 vs 64
7 sessions ago
AUPH +14
76 vs 62
30 sessions ago
AUPH +23
73 vs 50
90 sessions ago
AUPH +9
68 vs 59

The lead has not changed hands in this window.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

AUPHConflicted

2 bullish / 2 bearish, conflicted

Only AUPH

  • Golden Cross Active — bullish, trend, long horizon (4.77%)
  • Price Lost 200-Day MA — bearish, trend, long horizon
  • BB Lower Band Breach — bullish, volatility, short horizon
  • MACD Histogram Expanding Bearish — bearish, momentum, short horizon
BBIOConflicted

2 bullish / 2 bearish / 1 neutral, conflicted

Only BBIO

  • Death Cross Active — bearish, trend, long horizon (3.88%)
  • ADX Trend Strengthening — neutral, trend, medium horizon
  • EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
  • Low Volume Rally Warning — bearish, volume, short horizon (0.38x)
  • TRIX Bullish Signal — bullish, momentum, short horizon

AUPH leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

AUPHNo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -2.96%, AIQ 0 points).

BBIOConfirmed strength

Price and the AIQ Score both moved up over the latest session (price +0.17%, AIQ +1 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1BBIO closes the Value gap — currently 29 points behind, the largest single contributor to AUPH's edge.
  2. 2BBIO's Death Cross Active resolves — a bearish trend rule currently active against it.
  3. 3AUPH's conflicting signal state resolves bearish — it currently carries 2 bullish and 2 bearish rules at once.
  4. 4The narrowing continues — the lead has already given back 12 points over 30 sessions, and a further 11-point move would eliminate AUPH's advantage entirely.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

Split
MetricAUPHBBIO
Revenue growth (YoY)0.6%44.9%
EPS growth (YoY)-17.2%46.2%
Gross margin90.7%93.5%
Operating margin48.6%-43.4%
Return on equity (TTM)4.8%3.4%
Debt to equity0.09-1.5

Performance

BBIO leads 5 of 6 windows
MetricAUPHBBIO
1 week (5 sessions)-4.4%5.4%
1 month (20 sessions)-4.7%17.9%
3 months (63 sessions)2.9%-2%
6 months (126 sessions)2.9%18.4%
Year to date-1.4%2.4%
1 year (252 sessions)1.2%18.2%

Technicals

BBIO has the stronger structure
MetricAUPHBBIO
RSI (14)39.965
ADX (14)17.338.9
Price vs 50-day-4.6%11.9%
Price vs 200-day0%7.7%
Volatility (1M, annualized)36.7%39.1%

Risk

AUPH is the more resilient
MetricAUPHBBIO
Beta0.640.95
Sharpe ratio0.160.55
Sortino ratio0.230.84
Max drawdown-21.8%-29.8%
Current drawdown-15.5%-13.2%
Annualized volatility35.5%44.1%
Value at risk (95%)-3.4%-4%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, AUPH or BBIO?

On the Algovestiq AIQ Score, AUPH is the stronger of the two as of Nov 15, 2026, scoring 75 against BBIO's 64. The edge comes from value and quality. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is AUPH or BBIO the better buy right now?

AUPH carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Fragile — 3 of 6 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: only 3 of 6 covered evidence groups agree. Treat the lead as provisional.

Why does the AIQ Score favor AUPH over BBIO?

The composite weights Quality, Value, Momentum and Risk Resilience. AUPH leads Value by 29 points; AUPH leads Quality by 11 points; AUPH leads Risk Resilience by 6 points. AUPH leads on all four AIQ factor dimensions. Value is itself one of those four, so the sweep is not explained by BBIO simply being cheaper — it warrants extra scrutiny for unmodeled catalysts, forward expectations or event risk the factors do not capture.

Which has more analyst upside, AUPH or BBIO?

Analyst price targets imply +14.4% upside for AUPH and +42% for BBIO, so the Street currently favors BBIO. That points the opposite way to the AIQ Score, which favors AUPH. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, AUPH or BBIO?

AUPH is the better-valued of the two on the peer-relative Value factor. AUPH on the peer-relative Value factor, by 29 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, AUPH or BBIO?

BBIO on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, AUPH or BBIO?

AUPH on the Momentum factor, by 4 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, AUPH or BBIO?

AUPH is the more resilient of the two, so the other name carries the higher downside risk. AUPH on Risk Resilience, by 6 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is AUPH more profitable than BBIO?

The profitability evidence is mixed: gross margin 90.7% vs 93.5%; operating margin 48.6% vs -43.4%; ttm roe 4.8% vs 3.4%. AUPH leads on two measures and BBIO on one measure, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.

Is AUPH's lead over BBIO getting stronger or weaker?

AUPH lead: Weakening — the AIQ differential moved from 23 to 11 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has not changed hands in that window.

What would change the AUPH vs BBIO verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: BBIO closes the Value gap — currently 29 points behind, the largest single contributor to AUPH's edge; BBIO's Death Cross Active resolves — a bearish trend rule currently active against it; AUPH's conflicting signal state resolves bearish — it currently carries 2 bullish and 2 bearish rules at once; the narrowing continues — the lead has already given back 12 points over 30 sessions, and a further 11-point move would eliminate AUPH's advantage entirely.

What do the current signals say about AUPH and BBIO?

AUPH: 2 bullish / 2 bearish, conflicted. BBIO: 2 bullish / 2 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on AUPH is Golden Cross Active (bullish, long horizon). On BBIO it is Death Cross Active (bearish, long horizon).

Compare AUPH and BBIO with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.